Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Article Details

Citation

Cooper TM

Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Ther Clin Risk Manag. 2007 Dec;3(6):1135-41.

PubMed ID
18516261 [ View in PubMed
]
Abstract

T-cell malignancies have distinct biochemical, immunologic, and clinical features which set them apart from non-T-cell malignancies. In the past, T-cell leukemia portended a worse prognosis than leukemia of B-cell origin. Cure rates have improved with intensification of therapy and advanced understanding of the molecular genetics of T-cell malignancies. Further advances in the treatment of T-cell leukemia will require the development of novel agents that can target specific malignancies without a significant increase in toxicity. Nelarabine (2-amino-9beta-D-arabinosyl-6-methoxy-9H-guanine), a synthesized guanosine nucleoside prodrug of ara-G (9-beta-D-arabinofuranosylguanine), recently received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory T-ALL and T-LBL in adults and children. Nelarabine is water soluble and rapidly converted to ara-G, which is specifically cytotoxic to T-lymphocytes and T-lymphoblastoid cells. Clinical and pharmacokinetic investigations have established that nelarabine is active as a single agent which has led to exploration of an expanded role in the treatment of T-cell hematologic malignances.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
NelarabineDNANucleotideHumans
Yes
Incorporation into and destabilization
Details
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
NelarabineAdenosine deaminaseProteinHumans
No
Substrate
Details
NelarabineDeoxycytidine kinaseProteinHumans
No
Substrate
Details
NelarabineDeoxyguanosine kinase, mitochondrialProteinHumans
No
Substrate
Details